Reynders McVeigh Capital Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,106
| Closed | -$296K | – | 198 |
|
|
2025
Q4 | $296K | Buy |
3,106
+7
| +0.2% | +$686 | 0.01% | 161 |
|
|
2025
Q3 | $303K | Buy |
3,099
+185
| +6% | +$19.2K | 0.01% | 168 |
|
|
2025
Q2 | $313K | Sell |
2,914
-37
| -1% | -$3.74K | 0.02% | 166 |
|
|
2025
Q1 | $298K | Sell |
2,951
-150
| -5% | -$15.1K | 0.02% | 166 |
|
|
2024
Q4 | $277K | Hold |
3,101
| – | – | 0.01% | 171 |
|
|
2024
Q3 | $260K | Hold |
3,101
| – | – | 0.01% | 185 |
|
|
2024
Q2 | $239K | Hold |
3,101
| – | – | 0.01% | 181 |
|
|
2024
Q1 | $213K | Buy |
+3,101
| New | +$199K | 0.01% | 189 |
|
|
2020
Q4 | – | Sell |
-17,773
| Closed | -$679K | – | 225 |
|
|
2020
Q3 | $679K | Sell |
17,773
-264
| -1% | -$10.2K | 0.05% | 126 |
|
|
2020
Q2 | $633K | Sell |
18,037
-697
| -4% | -$25.1K | 0.06% | 125 |
|
|
2020
Q1 | $611K | Sell |
18,734
-751
| -4% | -$29.3K | 0.07% | 109 |
|
|
2019
Q4 | $881K | Sell |
19,485
-632
| -3% | -$26.4K | 0.08% | 113 |
|
|
2019
Q3 | $819K | Sell |
20,117
-2,000
| -9% | -$84.7K | 0.09% | 110 |
|
|
2019
Q2 | $951K | Buy |
22,117
+116
| +0.5% | +$4.46K | 0.1% | 100 |
|
|
2019
Q1 | $844K | Buy |
22,001
+1,800
| +9% | +$68.7K | 0.09% | 112 |
|
|
2018
Q4 | $714K | Buy |
20,201
+500
| +3% | +$18.1K | 0.09% | 106 |
|
|
2018
Q3 | $758K | Buy |
19,701
+350
| +2% | +$12.2K | 0.09% | 113 |
|
|
2018
Q2 | $633K | Buy |
19,351
+3,084
| +19% | +$93K | 0.08% | 124 |
|
|
2018
Q1 | $444K | Buy |
16,267
+800
| +5% | +$21.7K | 0.06% | 140 |
|
|
2017
Q4 | $383K | Sell |
15,467
-425
| -3% | -$11.7K | 0.05% | 156 |
|
|
2017
Q3 | $464K | Hold |
15,892
| – | – | 0.06% | 146 |
|
|
2017
Q2 | $441K | Sell |
15,892
-250
| -2% | -$6.63K | 0.06% | 149 |
|
|
2017
Q1 | $401K | Sell |
16,142
-2,525
| -14% | -$61.4K | 0.06% | 158 |
|
|
2016
Q4 | $404K | Sell |
18,667
-425
| -2% | -$9.27K | 0.06% | 157 |
|
|
2016
Q3 | $454K | Hold |
19,092
| – | – | 0.07% | 144 |
|
|
2016
Q2 | $446K | Hold |
19,092
| – | – | 0.06% | 146 |
|
|
2016
Q1 | $359K | Sell |
19,092
-766
| -4% | -$13.5K | 0.05% | 166 |
|
|
2015
Q4 | $366K | Hold |
19,858
| – | – | 0.06% | 144 |
|
|
2015
Q3 | $326K | Buy |
19,858
+2,102
| +12% | +$35.9K | 0.06% | 161 |
|
|
2015
Q2 | $314K | Buy |
17,756
+4,731
| +36% | +$84.5K | 0.05% | 163 |
|
|
2015
Q1 | $231K | Buy |
+13,025
| New | +$206K | 0.04% | 166 |
|
Other funds holding BSX
VCM
VPM
Reynders McVeigh Capital Management's BSX Position: Q1 2026 in Review
Reynders McVeigh Capital Management sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 3,106 shares — an estimated $296K sold.
Reynders McVeigh Capital Management first reported a position in BSX in Q1 2015 and held it in 31 quarters. The position peaked at $951K in Q2 2019. 1,671 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Reynders McVeigh Capital Management reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
- Reynders McVeigh Capital Management sold 3,106 Boston Scientific shares in Q1 2026, an estimated $296K.
- Reynders McVeigh Capital Management first reported a position in Boston Scientific in Q1 2015 and held it in 31 quarters.
- Reynders McVeigh Capital Management's Boston Scientific position peaked at $951K in Q2 2019.
- 1,671 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Reynders McVeigh Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.